- Title
- The use, misuse and abuse of dabigatran
- Creator
- Attia, John R.; Pearce, Robert
- Relation
- Medical Journal of Australia Vol. 198, Issue 7, p. 356-357
- Publisher Link
- http://dx.doi.org/10.5694/mja12.10729
- Publisher
- Australasian Medical Publishing Company
- Resource Type
- journal article
- Date
- 2013
- Description
- There has been much publicity and controversy about the role of dabigatran in the prevention of embolic stroke in those with atrial fibrillation since the landmark RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial was published in September 2009.1 In this perspective, we provide a critical appraisal of the original trial and highlight some concerns (“use”), review some of the issues about bleeding and inappropriate selection of patients (“misuse”), and detail some of the heated and unique politics around its attempted listing on the Pharmaceutical Benefits Scheme (PBS) in Australia (“abuse”).
- Subject
- dabigatran; embolic stroke; warfarin; atrial-fibrillation
- Identifier
- http://hdl.handle.net/1959.13/1046694
- Identifier
- uon:14670
- Identifier
- ISSN:0025-729X
- Language
- eng
- Hits: 3137
- Visitors: 2094
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|